Objective:To investigate the efficacy of Guanxinning Tablets as an adjunctive treatment for coronary heart disease complicated by insomnia in older adult patients. Methods:A total of 80 patients with coronary heart disease complicated by insomnia, admitted to The Second People's Hospital of Lishui between December 2021 and December 2023, were selected for this study. A randomized, controlled trial design was used, with patients randomly assigned to either the control group or the observation group ( n = 40/group). The control group received conventional treatment along with basic sleep-promoting interventions, while the observation group received Guanxinning Tablets in addition to the treatment provided to the control group. The treatment duration for both groups was 8 weeks. The therapeutic effects, frequency and duration of angina attacks, Pittsburgh Sleep Quality Index score, Seattle Angina Questionnaire score, serum levels of interleukin-6, tumor necrosis factor-alpha, vascular endothelial growth factor, and the incidence of adverse reactions were compared between the two groups. Results:The clinical efficacy of the observation group was significantly better than that of the control group ( Z = 2.07, P < 0.05). After treatment, the frequency and duration of angina attacks in the observation group were (1.02 ± 0.31) times/d and (1.35 ± 0.27) min, both of which were significantly lower and shorter than those in the control group [(1.54 ± 0.40) times/d, (1.71 ± 0.36) min, t = -6.50, -5.06, both P < 0.05]. The Pittsburgh Sleep Quality Index score in the observation group was (5.93 ± 1.28), which was significantly lower than that in the control group [(7.33 ± 2.05), t = -3.66, P < 0.05]. The Seattle Angina Questionnaire scores for all dimensions in the observation group were higher than those in the control group ( t = 2.81, 2.30, 2.97, 4.76, 4.24, all P < 0.05). The levels of interleukin-6 and tumor necrosis factor-alpha in the observation group were (13.48 ± 3.60) mg/L and (15.53 ± 3.83) μg/L, respectively, both of which were significantly lower than those in the control group [(16.26 ± 4.51) mg/L, (20.38 ± 3.92) μg/L, t = -3.05, -5.60, both P < 0.05]. The vascular endothelial growth factor level in the observation group was (128.26 ± 16.67) ng/L, which was significantly higher than that in the control group [(105.78 ± 14.35) ng/L, t = 6.46, P < 0.05]. There was no significant difference in the incidence of adverse reactions between the two groups ( P > 0.05). Conclusions:Guanxinning Tablets, as an adjunctive treatment for coronary heart disease complicated by insomnia, can significantly improve outcomes in older adults by alleviating angina symptoms, enhancing sleep quality, and reducing inflammatory responses, without increasing the incidence of drug-related adverse reactions.

Objective:To investigate the efficacy of Guanxinning Tablets as an adjunctive treatment for coronary heart disease complicated by insomnia in older adult patients. Methods:A total of 80 patients with coronary heart disease complicated by insomnia, admitted to The Second People's Hospital of Lishui between December 2021 and December 2023, were selected for this study. A randomized, controlled trial design was used, with patients randomly assigned to either the control group or the observation group ( n = 40/group). The control group received conventional treatment along with basic sleep-promoting interventions, while the observation group received Guanxinning Tablets in addition to the treatment provided to the control group. The treatment duration for both groups was 8 weeks. The therapeutic effects, frequency and duration of angina attacks, Pittsburgh Sleep Quality Index score, Seattle Angina Questionnaire score, serum levels of interleukin-6, tumor necrosis factor-alpha, vascular endothelial growth factor, and the incidence of adverse reactions were compared between the two groups. Results:The clinical efficacy of the observation group was significantly better than that of the control group ( Z = 2.07, P < 0.05). After treatment, the frequency and duration of angina attacks in the observation group were (1.02 ± 0.31) times/d and (1.35 ± 0.27) min, both of which were significantly lower and shorter than those in the control group [(1.54 ± 0.40) times/d, (1.71 ± 0.36) min, t = -6.50, -5.06, both P < 0.05]. The Pittsburgh Sleep Quality Index score in the observation group was (5.93 ± 1.28), which was significantly lower than that in the control group [(7.33 ± 2.05), t = -3.66, P < 0.05]. The Seattle Angina Questionnaire scores for all dimensions in the observation group were higher than those in the control group ( t = 2.81, 2.30, 2.97, 4.76, 4.24, all P < 0.05). The levels of interleukin-6 and tumor necrosis factor-alpha in the observation group were (13.48 ± 3.60) mg/L and (15.53 ± 3.83) μg/L, respectively, both of which were significantly lower than those in the control group [(16.26 ± 4.51) mg/L, (20.38 ± 3.92) μg/L, t = -3.05, -5.60, both P < 0.05]. The vascular endothelial growth factor level in the observation group was (128.26 ± 16.67) ng/L, which was significantly higher than that in the control group [(105.78 ± 14.35) ng/L, t = 6.46, P < 0.05]. There was no significant difference in the incidence of adverse reactions between the two groups ( P > 0.05). Conclusions:Guanxinning Tablets, as an adjunctive treatment for coronary heart disease complicated by insomnia, can significantly improve outcomes in older adults by alleviating angina symptoms, enhancing sleep quality, and reducing inflammatory responses, without increasing the incidence of drug-related adverse reactions.